Tonix Pharm Hldg Cmn (TNXP) 2.12 $TNXP
Tonix Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
GlobeNewswire - Thu Jul 07, 3:05PM CDT
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that it will present at Cantor Fitzgerald's 2 Annual Healthcare Conference being held July 12-13, 2016 in New York, NY.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Completes $10 Million Public Offering of Common Stock
GlobeNewswire - Tue Jun 21, 11:00AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock. The shares were sold at the public offering price of $2.00 per share, bringing the aggregate gross proceeds from the offering to $10 million, before deducting underwriting discounts and commissions and other offering expenses. The financing was led by healthcare focused institutional investors.
TNXP: 2.12 (-0.04), NHLD: 3.11 (+0.01)
Tonix Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
GlobeNewswire - Fri Jun 17, 7:00AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive officer of Tonix will present at the JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 1:00 p.m. ET in New York, NY.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia
GlobeNewswire - Thu Jun 09, 9:30AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia (FM) and post-traumatic stress disorder (PTSD), announced that today the company presented results from a retrospective analysis from its Phase 2b BESTFIT clinical study further supporting TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 2.8 mg for the treatment of fibromyalgia. Data were featured in a poster presentation at the European League Against Rheumatism (EULAR) Scientific Congress being held June 8-11, 2016 in London, England. The poster, titled, "TNX-102 SL for the Treatment of Fibromyalgia: Comparison of 30% Pain Responder Analysis with OMERACT Draft Composite Responder Endpoint Analyses," is available on Tonix's website at www.tonixpharma.com.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals to Present at the 2016 BIO International Convention
GlobeNewswire - Fri Jun 03, 6:00AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive officer of Tonix will present at the 2016 BIO International Convention on Tuesday, June 7, 2016 at 3:15 p.m. PT in San Francisco, CA.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) at the American Society of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting
GlobeNewswire - Tue May 31, 6:00AM CDT
-- Study Successfully Identified Effective and Well-tolerated Dose for Registration Studies
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting
GlobeNewswire - Thu May 26, 7:30AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced that it will present positive data from the Phase 2 dose-finding clinical study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of military-related PTSD (AtEase Study). Data will be featured in oral and poster presentations at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP, formerly NCDEU) being held May 30 - June 3, 2016 in Scottsdale, Arizona.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
GlobeNewswire - Thu May 19, 5:00AM CDT
-- Conference Call and Webcast Today at 8:00 a.m. ET
TNXP: 2.12 (-0.04)
Tonix reports 1Q loss
Automated Insights - Mon May 09, 7:01AM CDT
NEW YORK (AP) _ Tonix Pharmaceuticals Holding Corp. (TNXP) on Monday reported a loss of $14 million in its first quarter.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Programs Update
GlobeNewswire - Mon May 09, 6:00AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for common disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder (PTSD), announced financial results for the first quarter ended March 31, 2016.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia
GlobeNewswire - Mon May 02, 6:34AM CDT
- Top-line Results on Track to be Reported 3Q 2016 for Pivotal Study in Flagship Program -
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals to Present at the 10th Annual BIO Europe Spring Conference
GlobeNewswire - Tue Mar 29, 6:00AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Ronald Notvest, Ph.D., MBA, Executive Vice President, Commercial Planning and Development of Tonix, will present at the 10 Annual BIO Europe Spring Conference to be held at the Kistamassan Convention Center in Stockholm, Sweden on Tuesday, April 5, 2016 at 4:45 p.m. CET.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting
GlobeNewswire - Wed Mar 09, 6:00AM CST
- TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for bedtime administration currently under development for the long-term management of fibromyalgia and treatment of post-traumatic stress disorder-
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals to Present at the 28th Annual ROTH Conference
GlobeNewswire - Tue Mar 08, 3:05PM CST
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive officer of Tonix will present at the 28 Annual ROTH Conference on Tuesday, March 15, 2016 at 2:30 p.m. PT in Dana Point, California.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Programs Update
GlobeNewswire - Fri Mar 04, 6:00AM CST
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced financial results for the fourth quarter and full year ended December 31, 2015.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals to Present at Two Investor Conferences in March 2016
GlobeNewswire - Thu Mar 03, 6:00AM CST
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive officer of Tonix, will present a corporate update twice this month, at conferences sponsored by Cowen & Co. and BioCentury.
TNXP: 2.12 (-0.04)
Addiction Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/m28s26/addiction) has announced the addition of the "Addiction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Addiction Overview - Therapeutics Development - Pipeline Products for Addiction - Overview - Pipeline Products for Addiction - Comparative Analysis - Addiction - Therapeutics under Development by Companies - Addiction - Therapeutics under Investigation by Universities/Institutes - Addiction - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Addiction - Products under Development by Companies - Addiction - Products under Investigation by Universities/Institutes - Addiction - Companies Involved in Therapeutics Development Companies Mentioned - AbbVie Inc. - Addex Therapeutics Ltd - Adial Pharmaceuticals, LLC - Aelis Farma S.A.S. - Alkermes Plc - Aphios Corporation - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astellas Pharma Inc. - C4X Discovery Limited - Camurus AB - Embera NeuroTherapeutics, Inc. - Ethypharm S.A. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Grunenthal GmbH - H. Lundbeck A/S - Heptares Therapeutics Limited - Heron Therapeutics, Inc. - Immunovaccine, Inc. - Indivior Plc - INSYS Therapeutics, Inc. - InterveXion Therapeutics LLC - Neurocrine Biosciences, Inc. - Omeros Corporation - P2D Bioscience - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Tonix Pharmaceuticals Holding Corp. - VM Discovery, Inc. - XenoPort, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/m28s26/addiction
PFE: 36.15 (+0.03), ALKS: 49.19 (+0.24), ZYNE: 7.26 (-0.10), XNPT: 7.07 (+0.05), OMER: 11.74 (+0.15), INSY: 15.18 (-0.48), NBIX: 48.64 (+0.06), TNXP: 2.12 (-0.04), HRTX: 18.00 (-0.68), ABBV: 64.35 (+0.19), ARNA: 1.62 (-0.08)
Tonix Pharmaceuticals to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
GlobeNewswire - Thu Jul 07, 3:05PM CDT
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that it will present at Cantor Fitzgerald's 2 Annual Healthcare Conference being held July 12-13, 2016 in New York, NY.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Completes $10 Million Public Offering of Common Stock
GlobeNewswire - Tue Jun 21, 11:00AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock. The shares were sold at the public offering price of $2.00 per share, bringing the aggregate gross proceeds from the offering to $10 million, before deducting underwriting discounts and commissions and other offering expenses. The financing was led by healthcare focused institutional investors.
TNXP: 2.12 (-0.04), NHLD: 3.11 (+0.01)
Tonix Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
GlobeNewswire - Fri Jun 17, 7:00AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive officer of Tonix will present at the JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 1:00 p.m. ET in New York, NY.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia
GlobeNewswire - Thu Jun 09, 9:30AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia (FM) and post-traumatic stress disorder (PTSD), announced that today the company presented results from a retrospective analysis from its Phase 2b BESTFIT clinical study further supporting TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 2.8 mg for the treatment of fibromyalgia. Data were featured in a poster presentation at the European League Against Rheumatism (EULAR) Scientific Congress being held June 8-11, 2016 in London, England. The poster, titled, "TNX-102 SL for the Treatment of Fibromyalgia: Comparison of 30% Pain Responder Analysis with OMERACT Draft Composite Responder Endpoint Analyses," is available on Tonix's website at www.tonixpharma.com.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals to Present at the 2016 BIO International Convention
GlobeNewswire - Fri Jun 03, 6:00AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive officer of Tonix will present at the 2016 BIO International Convention on Tuesday, June 7, 2016 at 3:15 p.m. PT in San Francisco, CA.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) at the American Society of Clinical Psychopharmacology (ASCP) 2016 Annual Meeting
GlobeNewswire - Tue May 31, 6:00AM CDT
-- Study Successfully Identified Effective and Well-tolerated Dose for Registration Studies
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting
GlobeNewswire - Thu May 26, 7:30AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced that it will present positive data from the Phase 2 dose-finding clinical study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for the treatment of military-related PTSD (AtEase Study). Data will be featured in oral and poster presentations at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP, formerly NCDEU) being held May 30 - June 3, 2016 in Scottsdale, Arizona.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
GlobeNewswire - Thu May 19, 5:00AM CDT
-- Conference Call and Webcast Today at 8:00 a.m. ET
TNXP: 2.12 (-0.04)
Tonix reports 1Q loss
Automated Insights - Mon May 09, 7:01AM CDT
NEW YORK (AP) _ Tonix Pharmaceuticals Holding Corp. (TNXP) on Monday reported a loss of $14 million in its first quarter.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Programs Update
GlobeNewswire - Mon May 09, 6:00AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for common disorders of the central nervous system, including fibromyalgia and post-traumatic stress disorder (PTSD), announced financial results for the first quarter ended March 31, 2016.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia
GlobeNewswire - Mon May 02, 6:34AM CDT
- Top-line Results on Track to be Reported 3Q 2016 for Pivotal Study in Flagship Program -
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals to Present at the 10th Annual BIO Europe Spring Conference
GlobeNewswire - Tue Mar 29, 6:00AM CDT
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Ronald Notvest, Ph.D., MBA, Executive Vice President, Commercial Planning and Development of Tonix, will present at the 10 Annual BIO Europe Spring Conference to be held at the Kistamassan Convention Center in Stockholm, Sweden on Tuesday, April 5, 2016 at 4:45 p.m. CET.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting
GlobeNewswire - Wed Mar 09, 6:00AM CST
- TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for bedtime administration currently under development for the long-term management of fibromyalgia and treatment of post-traumatic stress disorder-
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals to Present at the 28th Annual ROTH Conference
GlobeNewswire - Tue Mar 08, 3:05PM CST
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive officer of Tonix will present at the 28 Annual ROTH Conference on Tuesday, March 15, 2016 at 2:30 p.m. PT in Dana Point, California.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Programs Update
GlobeNewswire - Fri Mar 04, 6:00AM CST
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced financial results for the fourth quarter and full year ended December 31, 2015.
TNXP: 2.12 (-0.04)
Tonix Pharmaceuticals to Present at Two Investor Conferences in March 2016
GlobeNewswire - Thu Mar 03, 6:00AM CST
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix), which is developing next-generation medicines for fibromyalgia and post-traumatic stress disorder (PTSD), announced today that Seth Lederman, M.D., president and chief executive officer of Tonix, will present a corporate update twice this month, at conferences sponsored by Cowen & Co. and BioCentury.
TNXP: 2.12 (-0.04)
Addiction Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/m28s26/addiction) has announced the addition of the "Addiction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Addiction Overview - Therapeutics Development - Pipeline Products for Addiction - Overview - Pipeline Products for Addiction - Comparative Analysis - Addiction - Therapeutics under Development by Companies - Addiction - Therapeutics under Investigation by Universities/Institutes - Addiction - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Addiction - Products under Development by Companies - Addiction - Products under Investigation by Universities/Institutes - Addiction - Companies Involved in Therapeutics Development Companies Mentioned - AbbVie Inc. - Addex Therapeutics Ltd - Adial Pharmaceuticals, LLC - Aelis Farma S.A.S. - Alkermes Plc - Aphios Corporation - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astellas Pharma Inc. - C4X Discovery Limited - Camurus AB - Embera NeuroTherapeutics, Inc. - Ethypharm S.A. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Grunenthal GmbH - H. Lundbeck A/S - Heptares Therapeutics Limited - Heron Therapeutics, Inc. - Immunovaccine, Inc. - Indivior Plc - INSYS Therapeutics, Inc. - InterveXion Therapeutics LLC - Neurocrine Biosciences, Inc. - Omeros Corporation - P2D Bioscience - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Tonix Pharmaceuticals Holding Corp. - VM Discovery, Inc. - XenoPort, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/m28s26/addiction
PFE: 36.15 (+0.03), ALKS: 49.19 (+0.24), ZYNE: 7.26 (-0.10), XNPT: 7.07 (+0.05), OMER: 11.74 (+0.15), INSY: 15.18 (-0.48), NBIX: 48.64 (+0.06), TNXP: 2.12 (-0.04), HRTX: 18.00 (-0.68), ABBV: 64.35 (+0.19), ARNA: 1.62 (-0.08)
